Oncodesign Precision Medicine (OPM) joined a Michael J. Fox Foundation (MJFF) program to develop potential therapies that target the LRRK2 protein, a key contributor to some forms of Parkinson’s disease. […] The post Oncodesign joins MJFF LRRK2 development collaboration appeared first on Parkinson's News Today.
